389 related articles for article (PubMed ID: 10553708)
1. Quinolone activity against anaerobes.
Appelbaum PC
Drugs; 1999; 58 Suppl 2():60-4. PubMed ID: 10553708
[TBL] [Abstract][Full Text] [Related]
2. Quinolone activity against anaerobes: microbiological aspects.
Appelbaum PC
Drugs; 1995; 49 Suppl 2():76-80. PubMed ID: 8549420
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility of anaerobes to quinolones in the United States.
Hecht DW; Wexler HM
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S2-8. PubMed ID: 8953099
[TBL] [Abstract][Full Text] [Related]
4. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Goldstein EJ
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S25-30. PubMed ID: 8953103
[TBL] [Abstract][Full Text] [Related]
5. Effect of quinolones on intestinal ecology.
Edlund C; Nord CE
Drugs; 1999; 58 Suppl 2():65-70. PubMed ID: 10553709
[TBL] [Abstract][Full Text] [Related]
6. [Quinolones: historic review].
Rothlin RP
Medicina (B Aires); 1999; 59 Suppl 1():3-7. PubMed ID: 10436548
[TBL] [Abstract][Full Text] [Related]
7. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
Cormican MG; Marshall SA; Jones RN
Diagn Microbiol Infect Dis; 1995 Jan; 21(1):51-4. PubMed ID: 7789097
[TBL] [Abstract][Full Text] [Related]
8. A critical review of the fluoroquinolones: focus on respiratory infections.
Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
Nord CE
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Bauernfeind A
J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates.
Goldstein EJ; Citron DM; Hunt Gerardo S; Hudspeth M; Merriam CV
Antimicrob Agents Chemother; 1997 May; 41(5):1193-5. PubMed ID: 9145900
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates.
Milatovic D; Schmitz FJ; Brisse S; Verhoef J; Fluit AC
Antimicrob Agents Chemother; 2000 Apr; 44(4):1102-7. PubMed ID: 10722524
[TBL] [Abstract][Full Text] [Related]
13. Comparative antianaerobic activity of BMS 284756.
Hoellman DB; Kelly LM; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2001 Feb; 45(2):589-92. PubMed ID: 11158759
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of grepafloxacin (OPC-17116) against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Diagn Microbiol Infect Dis; 1994 Jun; 19(2):129-33. PubMed ID: 7805357
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes.
Aldridge KE; Ashcraft DS
Antimicrob Agents Chemother; 1997 Mar; 41(3):709-11. PubMed ID: 9056020
[TBL] [Abstract][Full Text] [Related]
16. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria.
MacGowan AP; Bowker KE; Holt HA; Wootton M; Reeves DS
J Antimicrob Chemother; 1997 Oct; 40(4):503-9. PubMed ID: 9372419
[TBL] [Abstract][Full Text] [Related]
17. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
18. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.
Ednie LM; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Sep; 42(9):2459-62. PubMed ID: 9736586
[TBL] [Abstract][Full Text] [Related]
19. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria.
Ackermann G; Schaumann R; Pless B; Claros MC; Goldstein EJ; Rodloff AC
Eur J Clin Microbiol Infect Dis; 2000 Mar; 19(3):228-32. PubMed ID: 10795599
[TBL] [Abstract][Full Text] [Related]
20. Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents.
Peric M; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Aug; 48(8):3188-92. PubMed ID: 15273148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
